Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Fortrea Holdings Inc. (FTRE1) vs. Competitors

0 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
MX:FTRE1Fortrea Holdings Inc.MXN 373.00MXN 35.36B-26.230.00%Moderate BuyUnlock the MX:FTRE1 analyst price target with TipRanks PremiumMX:FTRE1Unlock the MX:FTRE1 top-analyst price target with TipRanks Premium
MRVIMaravai Lifesciences Holdings$7.40$1.92B-16.73103.30%Strong BuyUnlock the MRVI analyst price target with TipRanks PremiumMX:FTRE1 vs MRVIUnlock the MRVI top-analyst price target with TipRanks Premium
ABCLAbCellera Biologics$11.12$3.63B-23.18201.36%Strong BuyUnlock the ABCL analyst price target with TipRanks PremiumMX:FTRE1 vs ABCLUnlock the ABCL top-analyst price target with TipRanks Premium
RXRXRecursion Pharmaceuticals$2.91$1.81B-3.23-29.83%Moderate BuyUnlock the RXRX analyst price target with TipRanks PremiumMX:FTRE1 vs RXRXUnlock the RXRX top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$53.12$2.64B-17.49114.28%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumMX:FTRE1 vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
GENBGenerate Biomedicines, Inc.$10.49$1.35B-4.42-17.08%Moderate BuyUnlock the GENB analyst price target with TipRanks PremiumMX:FTRE1 vs GENBUnlock the GENB top-analyst price target with TipRanks Premium

Performance Comparison

-100%0%100%200%300%400%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
MX:FTRE1Fortrea Holdings Inc.373.000.000.00%
MRVIMaravai Lifesciences Holdings7.404.06121.56%
ABCLAbCellera Biologics11.127.52208.89%
RXRXRecursion Pharmaceuticals2.90-1.22-29.49%
MBXMBX Biosciences, Inc.53.1227.51107.42%
GENBGenerate Biomedicines, Inc.10.49-2.16-17.08%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts